News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment side-effects news

Show

From To
Hepatitis C treatment
Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection

The hepatitis C protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured hepatitis C in nearly three-quarters of people with genotype 1 hepatitis C virus

Published
05 March 2014
By
Liz Highleyman
Hepatitis C treatment
Six-week oral treatment can cure hard-to-treat hepatitis C patients

Interferon- and ribavirin-free treatment using sofosbuvir, ledipasvir and a third direct-acting drug for as little as six weeks can cure most previously untreated people with genotype 1

Published
04 March 2014
By
Liz Highleyman
Hepatitis C treatment
Low lymphocyte count a risk factor for infections for people taking HCV therapy

A low lymphocyte count is associated with an increased risk of infections during hepatitis C virus (HCV) treatment that includes pegylated interferon and ribavirin, according to the

Published
16 January 2014
By
Michael Carter
New and experimental hepatitis C treatment
Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection

The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks

Published
22 October 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Simeprevir with interferon effective for HIV/HCV co-infected people with genotype 1 hepatitis C

Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported

Published
21 October 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Interferon-free therapy alters lipid metabolism, glucose homeostasis in chronic HCV patients

Patients with chronic hepatitis C treated with an interferon-free regimen consisting of sofosbuvir and ribavirin experienced changes in LDL, triglycerides, hemoglobin A1C and metabolic and hepatic lipid gene expression in a study presented at ID Week 2013.

Published
14 October 2013
From
Healio Hepatology
New and experimental hepatitis C treatment
Daclatasvir works well against hepatitis C either with interferon or in all-oral regimen

A short 12- or 16-week triple regimen of daclatasvir plus pegylated interferon/ribavirin cured more people than a 24-week course of pegylated interferon/ribavirin alone, whilst an interferon-free regimen containing

Published
10 October 2013
By
Liz Highleyman
Hepatitis C treatment
Treating HCV genotypes 2 and 3 in HIV/HCV co-infected people

People co-infected with HIV and HCV, mostly with hepatitis C virus (HCV) genotype 3, responded about as well as HIV-negative people to interferon-based therapy after taking

Published
27 September 2013
By
Liz Highleyman
Hepatitis C treatment
HIV/HCV co-infected people can do well on hepatitis C triple therapy despite contraindications

Nearly three-quarters of HIV/HCV co-infected patients in the French HEPAVIH cohort achieved end-of-treatment virological response to hepatitis C treatment with telaprevir plus pegylated interferon/ribavirin, even though one-third had

Published
22 July 2013
By
Liz Highleyman
Hepatitis C treatment side-effects
Fear of future health problems encourage people to start and complete HCV therapy but concern about side-effects is a deterrent

US research has provided important insights into the factors that motivate and deter people from starting and completing therapy for hepatitis C virus (HCV) infection. Published in the

Published
28 June 2013
By
Michael Carter
← Prev12345Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.